SLIT mutations as potential predictive biomarkers for immunotherapy in NSCLC

Invest New Drugs. 2023 Apr;41(2):251-253. doi: 10.1007/s10637-023-01355-6. Epub 2023 Apr 10.

Authors

Tong Zhou¹, Huan Yi², Chan Zhu², Yangyang Yu², Qianru He², Mingzhe Xiao², Chuang Qi², Tianyu Lu³

Affiliations

¹ Medical Oncology Department, The Fourth People's Hospital of Changzhou, Changzhou, China.
² The State Key Laboratory of Translational Medicine and Innovative Drug Development, Jiangsu Simcere Diagnostics Co, No.699-18 Xuanwu Avenue, Nanjing, China.
³ Thoracic Surgery Department, The first hospital of Jilin University, No.71 Xinmin Street, Changchun, China. luty17@mails.jlu.edu.cn.

PMID: 37036581
DOI: 10.1007/s10637-023-01355-6

No abstract available

Publication types

Letter
Research Support, Non-U.S. Gov't

MeSH terms

Biomarkers
Biomarkers, Tumor / genetics
Carcinoma, Non-Small-Cell Lung* / drug therapy
Carcinoma, Non-Small-Cell Lung* / genetics
Humans
Immunotherapy
Lung Neoplasms* / drug therapy
Lung Neoplasms* / genetics
Mutation

Substances

Biomarkers
Biomarkers, Tumor